Qualigen Therapeutics (QLGN) Presents Data on QN-302 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
14.09.2022 - Posters include data regarding 1) mode of action, and 2) preclinical toxicology CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) - Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing . Seite 1
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302 forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results - read this article along with other careers information, tips and advice on BioSpace
Qualigen Therapeutics, Inc. Provides Update on Product globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.